An investigation for phylogenetic characterization of human pancreatic cancer microbiome by 16S rDNA sequencing and bioinformatics techniques

Abstract

Pancreatic cancer is a significant public health concern, with increasing incidence rates and limited treatment options. Recent studies have highlighted the role of the human microbiome, particularly the gut microbiota, in the development and progression of this disease. Microbial dysbiosis, characterized by alterations in the composition and function of the gut microbiota, has been implicated in pancreatic carcinogenesis through mechanisms involving chronic inflammation, immune dysregulation, and metabolic disturbances. Researchers have identified specific microbial signatures associated with pancreatic cancer, offering potential biomarkers for early detection and prognostication. By leveraging advanced sequencing and bioinformatics tools, scientists have delineated differences in the gut microbiota between pancreatic cancer patients and healthy individuals, providing insights into disease pathogenesis and potential diagnostic strategies. Moreover, the microbiome holds promise as a therapeutic target in pancreatic cancer treatment. Interventions aimed at modulating the microbiome, such as probiotics, prebiotics, and fecal microbiota transplantation, have demonstrated potential in enhancing the efficacy of existing cancer therapies, including chemotherapy and immunotherapy. These approaches can influence immune responses, alter tumor microenvironments, and sensitize tumors to treatment, offering new avenues for improving patient outcomes and overcoming therapeutic resistance. Overall, understanding the complex interplay between the microbiome and pancreatic cancer is crucial for advancing our knowledge of disease mechanisms and identifying innovative therapeutic strategies. Here we report phylogenetic analysis of the 16S rDNA microbial sequences of the pancreatic cancer mice microbiome and corresponding age matched healthy mice microbiome. We successfully identified differentially abundant microbiota in pancreatic cancer.

Keywords

Microbiome / Pancreatic Cancer / 16SrRNA / Phylogeny

AUTHORS CONTRIBUTIONS

All authors have equal contribution for this manuscript.

ETHICAL STATEMENT

All experiments including animal studies were done ethi-cally and following approved protocols as described in the manuscript and data presented true to our knowledge.

FUNDING

This research was supported by NIH-MARC Grant# T34 GM100831to Dr. H. Banerjee, DOE HBCU and NSF NOYCE Graduate training grant to Elizabeth City State University and A UNC Collaboratory research award to Dr. Colby Hunter.

CONFLICTS OF INTEREST DISCLOSURE

The authors declare no conflict of interest.

ETHICS APPROVAL

The Publication Ethics Committee of the Sciedu Press. The journal’s policies adhere to the Core Practices established by the Committee on Publication Ethics (COPE).

PROVENANCE AND PEER REVIEW

Not commissioned; externally double-blind peer reviewed.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

DATA SHARING STATEMENT

No additional data are available.

OPEN ACCESS

This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).

COPYRIGHTS

Copyright for this article is retained by the author(s), with first publication rights granted to the journal.

References

[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72(1). PMid: 35020204. https://doi.org/10.3322/caac.21708

[2] Wood LD, Canto MI, Jaffee EM, et al. Pancreatic cancer: pathogene-sis, screening, diagnosis, and treatment. Gastroenterology. 2022; 163:386-402, e381. PMid: 35398344. https://doi.org/10.1053/j.gastro.2022.03.056

[3] Li Q, Jin M, Liu Y, et al. Gut Microbiota: Its Potential Roles in Pancreatic Cancer. Frontiers in Cellular and Infection Microbiology. 2020; 10: 572492. PMid: 33117731. https://doi.org/10.3389/fcimb.2020.572492

[4] Zhang Z, Tang D. The Huge Clinical Potential of Microbiota in the Treatment of Pancreatic Cancer: the Next Frontier. Biochim Biophys Acta Rev Cancer. 2022; 1877: 188733. PMid: 35483491. https://doi.org/10.1016/j.bbcan.2022.188733

[5] Huang Y, Zhu N, Zheng X, et al. Intratumor Microbiome Analysis Identifies Positive Association Between. Frontiers in immunology. 2022; 13: 785422. PMid: 351455191. https://doi.org/10.3389/fimmu.2022.785422

[6] Xu H, Cao C, Ren Y, et al. Antitumor effects of fecal microbiota transplantation: implications for microbiome modulation in cancer treatment. Front Immunol. 2022; 13: 949490. PMid: 36177041. https://doi.org/10.3389/fimmu.2022.949490

[7] Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratu-mor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017; 357(6356): 1156-1160. PMid: 28912244. https://doi.org/10.1126/science.aah5043

[8] Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic can-cer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018; 8 : 403-416. PMid: 29567829. https://doi.org/10.1158/2159-8290.CD-17-1134

[9] Aykut B, Pushalkar S, Chen R, et al. The fungal mycobiome pro-motes pancreatic oncogenesis via activation of MBL. Nature. 2019; 574: 264-267. PMid: 31578522. https://doi.org/10.1038/s41586-019-1608-2

[10] Riquelme E, Zhang Y, Zhang L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019; 178: 795-806, e712. PMid: 31398337. https://doi.org/10.1016/j.cell.2019.07.008

[11] Guo W, Zhang Y, Guo S, et al. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Commun Biol. 2021; 4: 1019. PMid: 34465850. https://doi.org/10.1038/s42003-021-02557-5

[12] Gleeson FC, Jeraldo P, Levy MJ, et al. Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. Gut. 2022; 71: 441-443. PMid: 33753418. https://doi.org/10.1136/gutjnl-2021-324031

[13] Panebianco C, Ciardiello D, Villani A, et al. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic per-spective. Semin Cancer Biol. 2021; 86: 997-1007. PMid: 34838957. https://doi.org/10.1016/j.semcancer.2021.11.007

[14] Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022; 185: 1356-1372, e1326. PMid: 35395179. https://doi.org/10.1016/j.cell.2022.02.027

[15] Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020; 368: 973-980. PMid: 32467386. https://doi.org/10.1126/science.aay9189

[16] Walker SP, Tangney M, Claesson MJ. Sequence-based characteriza-tion of intratumoral bacteria-A guide to best practice. Front Oncol. 2020; 10: 179. PMid: 32154174. https://doi.org/10.3389/fonc.2020.00179

[17] Gonzalez-Sanchez P, DeNicola GM. The microbiome(s) and can-cer: know thy neighbor(s). J Pathol. 2021; 254: 332-343. PMid: 33723873. https://doi.org/10.1002/path.5661

[18] Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30: 492-506. PMid: 32433595. https://doi.org/10.1038/s41422-020-0332-7

[19] Riquelme E, Maitra A, McAllister F. Immunotherapy for pancreatic cancer: more than just a gut feeling. Cancer Discov. 2018; 8: 386-388. PMid:29610286. https://doi.org/10.1158/2159-8290.CD-18-0123

[20] Leinwand J, Miller G. Regulation and modulation of antitumor immu-nity in pancreatic cancer, Nat. Immunol. 2020; 21: 1152-1159. PMid: 32807942. https://doi.org/10.1038/s41590-020-0761-y

[21] Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology. 2018; 155: 33-37, e36. PMid: 29630898. https://doi.org/10.1053/j.gastro.2018.04.001

[22] Shi Y, Zheng W, Yang K, et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING sig-naling. J. Exp. Med. 2020; 217. PMid: 32142585. https://doi.org/10.1084/jem.20192282

[23] Brusilovsky M, Bao R, Rochman M, et al. Host-microbiota inter-actions in the esophagus during homeostasis and allergic inflamma-tion. Gastroenterology. 2022; 162: 521-534, e528. PMid: 34627858. https://doi.org/10.1053/j.gastro.2021.10.002

[24] Ahn J, Chen CY, Hayes RB. Oral microbiome and oral and gastroin-testinal cancer risk, Cancer Causes Control. 2012; 23: 399-404. PMid: 22271008. https://doi.org/10.1007/s10552-011-9892-7

[25] Gaiser RA, Halimi A, Alkharaan H, et al. Enrichment of oral micro-biota in early cystic precursors to invasive pancreatic cancer. Gut. 2019; 68: 2186-2194. PMid: 30872392. https://doi.org/10.1136/gutjnl-2018-317458

[26] O’grendik M. Oral bacteria in pancreatic cancer: mutagenesis of the p53 tumour suppressor gene. Int J Clin Exp Pathol. 2015; 8: 11835-11836.

[27] Xie Y, Xie F, Zhou X, et al. Microbiota in tumors: from understand-ing to application. Adv Sci. 2022; 9: e2200470. PMid: 35603968. https://doi.org/10.1002/advs.202200470

[28] Dehoux P, Marvaud JC, Abouelleil A, et al. Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resis-tance determinants. BMC Genomics. 2016; 17. PMid: 27769168. https://doi.org/10.1186/s12864-016-3152-x

[29] Zhou W, Zhang D, Li Z, et al. The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis char-acterized by metagenomic sequencing. J Transl Med. 2021; 19. PMid: 34006295. https://doi.org/10.1186/s12967-021-02882-7

[30] Dilmore AH, McDonald D, Nguyen TT, et al. The Fecal Microbiome and Metabolome of Pitt Hopkins Syndrome, a Severe Autism Spec-trum Disorder. 2021. PMid: 34846164. https://doi.org/10.1128/mSystems.01006-21

[31] Krueger C, Azad MA, Ramotar K, et al. Robinsoniella peorien-sis: An emerging pathogen and rare cause of wound infection in children. Journal of the Association of Medical Microbiology and Infectious Disease Canada. 2022; 7: 279-282. PMid: 36337600. https://doi.org/10.3138/jammi-2021-0038

[32] Shen D, Chen R, Ye L, et al. Robinsoniella peoriensis bacteremia in a patient with pancreatic cancer. J Clin Microbiol. 2010; 48: 3448-3450. PMid: 20631102. https://doi.org/10.1128/JCM.00477-10

[33] Mejia-Gomez J, Zigras T, Patel Y, et al. First reported case of Robin-soniella peoriensis pyometra and bloodstream infection: A case report and review of the literature. Anaerobe. 2022; 75. PMid: 35526662. https://doi.org/10.1016/j.anaerobe.2022.102581

[34] Kharofa J, Apewokin S, Alenghat T, et al. Metagenomic analysis of the fecal microbiome in colorectal cancer patients compared to healthy controls as a function of age. Cancer Med. 2023; 12: 2945-2957. PMid: 36056757. https://doi.org/10.1002/cam4.5197

[35] Chan AA, Bashir M, Rivas MN, et al. Characterization of the micro-biome of nipple aspirate fluid of breast cancer survivors. Sci Rep. 2016; 6. PMid: 27324944. https://doi.org/10.1038/srep28061

[36] Jin Y, Dong H, Xia L, et al. The Diversity of Gut Microbiome is Associated with Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. Journal of Tho-racic Oncology. 2019; 14: 1378-1389. PMid: 31026576. https://doi.org/10.1016/j.jtho.2019.04.007

[37] Luo ZW, Xia K, Liu YW, et al. Extracellular vesicles from akkerman-sia muciniphila elicit antitumor immunity against prostate cancer via modulation of CD8+ T cells and macrophages. Int J Nanomedicine. 2021; 16: 2949-2963. PMid: 33907401. https://doi.org/10.2147/IJN.S304515

[38] Shi L, Sheng J, Chen G, et al. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance. J Immunother Cancer. 2020; 8. PMid: 33028692. https://doi.org/10.1136/jitc-2020-000973

[39] Chen Z, Qian X, Chen S, et al. Akkermansia muciniphila Enhances the Antitumor Effect of Cisplatin in Lewis Lung Cancer Mice. J Immunol Res. 2020. PMid: 32832569. https://doi.org/10.1155/2020/2969287

[40] Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017.

[41] Derosa L, Routy B, Thomas AM, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine. 2022; 28(2): 315-324. PMid: 35115705. https://doi.org/10.1038/s41591-021-01655-5

[42] Wang K, Wu W, Wang Q, et al. The negative effect of Akker-mansia muciniphila-mediated post-antibiotic reconstitution of the gut microbiota on the development of colitis-associated colorec-tal cancer in mice. Front Microbiol. 2022; 13. PMid: 36312913. https://doi.org/10.3389/fmicb.2022.932047

[43] Dingemanse C, Belzer C, van Hijum SAFT, et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. Carcinogenesis. 2015; 36: 1388-1396. PMid: 26320104. https://doi.org/10.1093/carcin/bgv120

[44] Wang F, Cai K, Xiao Q, et al. Akkermansia muciniphila adminis-tration exacerbated the development of colitis-associated colorectal cancer in mice. J Cancer. 2022; 13: 124-133. PMid: 34976176. https://doi.org/10.7150/jca.63578

[45] Gubernatorova EO, Gorshkova EA, Bondareva MA, et al. Akkerman-sia muciniphila -friend or foe in colorectal cancer? Front Immunol. 2023; 14. PMid: 38124735. https://doi.org/10.3389/fimmu.2023.1303795

[46] Ottman N, Davids M, Suarez-Diez M, et al. Genome scale model and omics analysis of metabolic capacities of Akkermansia muciniphila reveal a preferential mucin-degrading lifestyle. Appl Environ Micro-biol. 2017; 83. PMid: 28687644. https://doi.org/10.1128/AEM.01014-17

[47] Tjalsma H, Boleij A, Marchesi JR, et al. A bacterial driver-passenger model for colorectal cancer: Beyond the usual suspects. Preprint. 2012. PMid: 22728587. https://doi.org/10.1038/nrmicro2819

[48] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet. 1984; 323(8390): 1311-1315. PMid: 6145023. https://doi.org/10.1016/S0140-6736(84)91816-6

[49] Cullin N, Antunes CA, Straussman R, et al. Microbiome and Cancer. Cell. 2021. PMid: 34506740. https://doi.org/10.1016/j.ccell.2021.08.006

[50] Derosa L, Hellmann MD, Spaziano M, et al. Negative Association of Antibiotics on Clinical Activity of Immune Checkpoint Inhibitors in Patients with Advanced Renal Cell and Non-Small-Cell Lung Cancer. Annals of Oncology. 2018; 29:1437-1444. PMid: 29617710. https://doi.org/10.1093/annonc/mdy103

[51] Willing B, Russell S. Finlay B. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol. 2011; 9: 233-243. PMid: 21358670. https://doi.org/10.1038/nrmicro2536

[52] Sheflin AM, Whitney AK, Weir TL. Cancer-Promoting Effects of Mi-crobial Dysbiosis. Curr Oncol Rep. 2014; 16: 406. PMid: 25123079. https://doi.org/10.1007/s11912-014-0406-0

[53] Ahmed J, Kumar A, Parikh K, et al. Use of Broad-Spectrum An-tibiotics Impacts Outcome in Patients Treated with Immune Check-point Inhibitors. Oncology. 2018; 11: 7. PMid: 30377571. https://doi.org/10.1080/2162402X.2018.1507670